Immunovant (IMVT) Other Operating Expenses (2019 - 2023)

Immunovant's (IMVT) quarterly Other Operating Expenses came in at $12.5 million in Q2 2023, up 25.0% on a QoQ basis from $10.0 million in Q4 2022.

Analysis

Immunovant (IMVT) Other Operating Expenses (2019 - 2023) Analysis & Trends

Immunovant (IMVT) has 3 years of Other Operating Expenses data on file, last reported at $12.5 million in Q2 2023.

Quarterly Other Operating Expenses changed N/A year-over-year to $12.5 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $12.5 million (up 25.0% YoY) and the FY2024 annual result came in at $12.5 million, up 25.0% from the prior year.
Other Operating Expenses improved to $12.5 million in Q2 2023, from $10.0 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $12.5 million in Q2 2023 to a low of -$8.9 million in Q1 2019.
A 3-year average of $4.5 million and a median of $10.0 million in 2022 frame the typical range for Other Operating Expenses.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.31 Bn	131.46 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.65 Bn	77.66 Bn	3.93 Bn
3	Argenx Se	63.46 Bn	58.27 Bn	1.37 Bn
4	Moderna	57.94 Bn	52.80 Bn	52.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-
6	BeOne Medicines	39.96 Bn	34.86 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.16 Bn	31.85 Bn	992.69 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn
10	Immunovant	8.04 Bn	8.04 Bn	-

Historic Data

Download Data